Kaveh Farrokhi

Dr. Kaveh Farrokhi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in Immunology
Verified
Journal Article
Open access
PDF file
Reginald M. GorczynskiReginald M. Gorczynski
Reginald M. Gorczynski
Kaveh FarrokhiKaveh Farrokhi
Kaveh Farrokhi
CGChristopher Gorczynski
Christopher Gorczynski
HSHassan Sadozai
Hassan Sadozai
FZFang Zhu
Fang Zhu
IKIsmat Khatri
Ismat Khatri
Summary: We previously showed that congenic bone marrow transplantation (BMTx) post myeloablation augmented tissue allograft survival in association with increased regulatory T (Treg) cells of both host and bone marrow donor origin. Regulatory B (Breg) cells can also modulate T‐cell immunity and B cells may be implicated in the development of Treg cells. Accordingly, we explored the effect of B‐cell depletion in vivo on augmented graft survival post BMTx. C57BL/6 mice received BALB/c skin allografts followed 7 days later by myeloablation using cyclophosphamide and busulphan. Mice then received T‐cell‐depleted bone marrow from CD45.1 congenic donors, and ongoing immunosuppression with rapamycin (to day 28 after BMTx). Control mice received cyclophosphamide and busulphan followed by rapamycin, but not congenic bone marrow. At different times post BMTx, mice received B‐cell‐depleting antibody treatment, and the effect on both skin graft survival, and induction of Treg cells was assessed. BMTx resulted in significantly prolonged skin graft survival versus control mice, in association with attenuated donor‐specific alloreactivity relative to controls, increased splenic Treg cells and significantly diminished anti‐donor IgG. In mice receiving infusion of B‐depleting antibodies for 12 days from day 15 post BMTx, both graft survival and Treg cell activity were diminished, particularly for functional Treg cells of donor origin. Adoptive transfer of Breg cells from mice harvested at 15 days post BMTx prolonged survival in naive transplanted mice and increased Treg cell levels. Thus, autologous BMTx augmentation of graft survival is dependent in part upon a population of Breg cells that can modulate the function of donor‐derived Treg cells.

2 April 2023 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
HSHassan Sadozai
Hassan Sadozai
VRVanessa Rojas-Luengas
Vanessa Rojas-Luengas
Kaveh FarrokhiKaveh Farrokhi
Kaveh Farrokhi
SMSajad Moshkelgosha
Sajad Moshkelgosha
QGQinli Guo
Qinli Guo
ACAndrzej Chruscinski
Andrzej Chruscinski
The ability to induce tolerance would be a major advance in the field of solid organ transplantation. Here, we investigated whether autologous (congenic) hematopoietic stem cell transplantation (HSCT) could promote tolerance to heart allografts in mice. In an acute rejection model, fully MHC-mismatched BALB/c hearts were heterotopically transplanted into C57BL/6 (CD45.2) mice. One week later, recipient mice were lethally irradiated and reconstituted with congenic B6 CD45.1 Lin -Sca1 +ckit + cells. Recipient mice received a 14-day course of rapamycin both to prevent rejection and to expand regulatory T cells (Tregs). Heart allografts in both untreated and rapamycin-treated recipients that did not undergo HSCT were rejected within 33 days (median survival time=8 days for untreated recipients, median survival time=32 days for rapamycin-treated recipients), whereas allografts in HSCT-treated recipients had a median survival time of 55 days (P<0.001 versus both untreated and rapamycin-treated recipients). Enhanced allograft survival following HSCT was associated with increased intragraft Foxp3 + Tregs, reduced intragraft B cells, and reduced serum donor-specific antibodies. In a chronic rejection model, Bm12 hearts were transplanted into C57BL/6 (CD45.2) mice, and congenic HSCT was performed two weeks following heart transplantation. HSCT led to enhanced survival of allografts (median survival time=70 days versus median survival time=28 days in untreated recipients, P<0.01). Increased allograft survival post-HSCT was associated with prevention of autoantibody development and absence of vasculopathy. These data support the concept that autologous HSCT can promote immune tolerance in the setting of allotransplantation. Further studies to optimize HSCT protocols should be performed before this procedure is adopted clinically.

26 June 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Kaveh FarrokhiKaveh Farrokhi
Kaveh Farrokhi
HMHoria Marginean
Horia Marginean
AAAnas A. Alghamdi
Anas A. Alghamdi
EMEssa Al Mansor
Essa Al Mansor
SDShaan Dudani
Shaan Dudani
Michael VickersMichael Vickers
Michael Vickers
Background: The impact of adjuvant chemotherapy (AC) on outcomes in real-world patients with locally advanced rectal cancer (LARC) remains uncertain. Methods: Consecutive patients with LARC (stage II/III) undergoing neoadjuvant chemoradiation before curative-intent surgery from 2005 to 2013 were identified in the Canadian Health Outcomes Research Database. The impact of AC on clinical outcomes, including disease-free survival (DFS) and overall survival (OS), was evaluated using the Kaplan–Meier method and Cox proportional hazards modeling. Results: A total of 1448 patients had sufficient data available to be included for analysis with 1085 (74.9%) receiving AC. Of AC patients, 40.5% received oxaliplatin-based treatments. With a median follow-up of 66.43 months, the 5-year DFS rate was 67.7% (95% CI: 64.5–70.1%) vs. 58.7% (95% CI: 52.8–64.2%) in the AC group and non-AC group, respectively (p < 0.001). The 5-year OS rate of the whole cohort was 74.3% (95% CI: 71.5–76.85%) while the 5-year OS rate of the AC group was 77.8% (95% CI: 74.7–80.6%) compared with 63.8% (95% CI: 57.9–69.2%) for the non-AC group (p < 0.001). On multivariate analysis, patients who received AC had improved DFS (HR 0.6, 95% CI: 0.49–0.73, p < 0.001) and OS (HR 0.46, 95% CI: 0.36–0.58, p < 0.001). Conclusions: This large multi-institutional database analysis supports the use of AC in real-world LARC patients treated with nCRT followed by surgical resection.

5 November 2024 in Blood
Verified
Journal Article
Closed access
JTJames Troyer
James Troyer
BLBonnie Lu
Bonnie Lu
KKKathryn Krause
Kathryn Krause
MAMelanie Aviles
Melanie Aviles
SDSherraine Della-Moretta
Sherraine Della-Moretta
WFWarren B. Fingrut
Warren B. Fingrut
Introduction: Health equity is increasingly being recognized as a critical priority across medicine. Through an initiative of the ASH Health Equity Task Force, we recently published the ASH Health Equity Compendium (Fingrut et al, Blood Adv. 2024) to describe/catalogue the health equity manuscripts published across the Blood journals. Extending from this work, herein we report the results of a scoping review of health equity in hematology. We aimed to gather published articles together to highlight hematology health equity works, note areas that would benefit from more attention and inspire efforts to spearhead projects characterizing/addressing disparities. Methods: We applied PRISMA-P extension guidelines to develop/publish a scoping review protocol, https://osf.io/exuzc. Articles were eligible if focused on health equity in hematology and published in one of 22 hematology journals 1/1/18-3/13/24 or 46 oncology/medicine/pediatrics journals 1/1/18-4/4/24 which had an impact factor >9.2 or were listed in Clarivate's Journal Citation Reports first quartile or were a major hematology/oncology society's official journal. A research librarian crafted a search to retrieve all articles with ≥1 health equity subject heading or ≥1 title/abstract health equity keyword from a predefined list. Articles underwent title/abstract then full text review and data extraction by 2 independent team members. All extracted data were published to docs.google.com/spreadsheets/d/1rFeGrNVdIDnYEzL9KPB1rqyZUafWGcoN11FsKGUzyCY. Results: The search returned 5,494 articles; 1,009 underwent full-text screening with 602 included in the review. The greatest number of articles were published in Pediatric Blood & Cancer (n=77) and Blood Advances (n=65), with the highest proportions in Lancet Haematology (3.3%) and Transplantation and Cellular Therapy (3.1%). Most articles were about patients, with 64 (11%) about blood/stem cell donors and 26 (4%) the workforce. 132 (22%) had a pediatric/adolescent/young adult focus. 262 (44%) were retrospective studies, with 116 (19%) prospective/trials and 23 studying basic science correlates of disparities. Only 64 (11%) described interventions to advance equity, 20 (3%) social determinants of health data collection process improvement and 1 health equity educational initiatives. Of 427 research articles (ie excluding 175 editorials/reviews), nearly half (204/427, 48%) reported disparities in disease phenotype/outcomes, with 69/427 (16%) on access to care. Of 562 disease-related articles, most (372/562, 66%) examined hematologic malignancies or BMT/cell therapy with only one third (190/562, 34%) about classical hematologic conditions. Most articles (342/602, 57%) focused on racial/ethnic disparities, with 239 (40%) on socioeconomics; 87 (14%) sex/parity; 65 (11%) geographic; 54 (9%) age; and 46 (8%) sexual/gender minorities (22 on transgender peoples). Less than a third (179/602, 30%) considered intersectionality across disparities. Only 12 focused on Indigenous peoples, 5 disability, 8 religion, 9 immigration and 2 incarceration. Only 8 noted partnerships with the populations impacted. Analyzing by year from 2018-2023, health equity articles increased over time, with nearly two thirds (356/545, 65%) of included articles published 2021-2023 versus one third (189/545, 35%) 2018-2020, p<.001. Focusing on the 22 included hematology journals, 491 health equity articles were published 2018-2023, reflecting 1.1% of all articles published in those journals over these years. Hematology journals also had a 75% increase in the proportion of health equity articles in the recent vs earlier periods (0.8% vs 1.4%, p<.001). Conclusion: Our analysis, the first of its kind to our knowledge, highlights recent progress characterizing inequities and clarifies areas warranting further study (eg disparities impacting understudied populations with consideration of intersectionality, across classical and malignant hematologic disorders, and testing interventions to address disparities, partnering with advocates from populations impacted). We also establish benchmarks for the proportion of health equity articles published, within/across journals. This review will serve as an important educational resource to advance equity, helping researchers and the field in general to assimilate the rapidly expanding hematology health equity literature